Analysts Set Roche Holding AG (OTCMKTS:RHHBY) Price Target at $57.00

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and three have issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $57.00.

Several analysts recently issued reports on RHHBY shares. Jefferies Financial Group downgraded Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Hsbc Global Res upgraded Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Barclays upgraded shares of Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a research report on Monday, December 8th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd.

Roche Trading Up 0.3%

Shares of OTCMKTS RHHBY opened at $53.34 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.29 and a quick ratio of 1.02. The firm’s 50-day moving average price is $49.20 and its two-hundred day moving average price is $44.10. Roche has a 52-week low of $34.75 and a 52-week high of $53.90.

Institutional Trading of Roche

Large investors have recently added to or reduced their stakes in the business. Curio Wealth LLC acquired a new position in Roche during the 3rd quarter worth $25,000. Oakworth Capital Inc. bought a new stake in shares of Roche during the third quarter valued at about $57,000. First Horizon Advisors Inc. lifted its holdings in Roche by 81.2% in the second quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after purchasing an additional 826 shares during the period. Salomon & Ludwin LLC grew its position in Roche by 256.6% in the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after buying an additional 2,053 shares in the last quarter. Finally, Douglass Winthrop Advisors LLC acquired a new position in Roche during the 3rd quarter valued at about $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.